Any reported adverse effects 6‐12 months after initiating the intervention (long term) · bipolar disorder
Lamotrigine probably leads to lower any reported adverse effects 6‐12 months after initiating the… compared with lithium (moderate certainty).
1 finding from 1 review
Treatment withdrawal · bipolar disorder
It is very uncertain whether lamotrigine changes withdrawal from treatment due to any reason, up to 12 weeks after… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal from treatment due to any reason, 6‐12 months after intervention initiation (long term) · bipolar disorder
Lamotrigine probably leads to lower withdrawal from treatment due to any reason, 6‐12 months after… compared with placebo (moderate certainty).
1 finding from 1 review
Any reported adverse effects 6‐12 months after initiating the intervention (long term) · bipolar disorder
Lamotrigine showed no clear difference in any reported adverse effects 6‐12 months after initiating the… compared with placebo (moderate certainty).
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Secondary outcome measure: lower extremity function at the end of · people with stroke
2 findings from 1 review
Muscle strength · people with stroke
2 findings from 1 review
Secondary outcome measure: cognitive abilities at the end of · people with stroke
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Secondary outcome measure: spatial neglect at the end of the intervention period · people with stroke
1 finding from 1 review
Dropouts, adverse events and deaths during intervention phase Numbers of dropouts, adverse events and deaths from all causes · people with stroke
tDCS showed no clear difference in secondary outcome measure: dropouts, adverse events and deaths… compared with any type of active control intervention (moderate certainty).
1 finding from 1 review
Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity. · people with stroke
1 finding from 1 review
ADL outcome · people with stroke
The review found no eligible studies for this question.
2 findings from 1 review
Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity. · people with stroke
2 findings from 1 review
Secondary outcome measure: lower extremity function at the end of · people with stroke
1 finding from 1 review
Muscle strength · people with stroke
1 finding from 1 review
Secondary outcome measure: cognitive abilities at the end of · people with stroke
1 finding from 1 review
Secondary outcome measure: hemispatial neglect at the end of · people with stroke
1 finding from 1 review
Dropouts, adverse events and deaths during intervention phase Numbers of dropouts, adverse events and deaths from all causes · people with stroke
tDCS showed no clear difference in secondary outcome measure: dropouts, adverse events and deaths… compared with any type of placebo or passive control intervention (moderate certainty).
1 finding from 1 review
Any complication requiring surgical intervention ‐ NRSs ( · women of reproductive age (15 to 49 years) seeking induced abortion
The review found no eligible studies for this question.
2 findings from 1 review
Any pain‐related outcome indicating some improvement · adults with neuropathic pain
1 finding from 1 review